NGS-based RNA-sequencing Market Size, Share and Growth Outlook 2026: By Product and Service, By Technology, By Sequencing Type, By Application, By End-User, Companies to 2034
The global NGS-based RNA-sequencing Market size is forecast to increase from $5.39 Billion in 2026 to $20.4 Billion in 2034 at a CAGR of 18.1% between 2026 and 2034.
The NGS-based RNA-sequencing market report provides detailed analysis and outlook of NGS-based RNA-sequencing segments including By Product and Service (Consumables, Sample Extraction and Purification Kits, Library Preparation Kits, Sequencing Reagents and Flow Cells, Instruments / Sequencing Platforms, Services, RNA-Sequencing Services, Bioinformatics and Data Analysis Services), By Technology (Sequencing by Synthesis (SBS), Ion Torrent Semiconductor Sequencing, Nanopore Sequencing, Single-Molecule Real-Time (SMRT) Sequencing), By Sequencing Type (Whole Transcriptome Sequencing, Targeted RNA Sequencing, Single-Cell RNA Sequencing), By Application (Drug Discovery and Development, Clinical Diagnostics, Biomarker Discovery, Basic Agriculture and Life Science Research), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Clinical and Diagnostic Laboratories, Contract Research Organizations (CROs)) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
NGS-based RNA-Sequencing Industry Overview
Transcriptomics Is Becoming a Core Technology for Precision Medicine and Biopharmaceutical Development
The NGS-based RNA-sequencing industry has evolved into a critical segment of the broader genomics market, enabling comprehensive analysis of gene expression, transcript variants, alternative splicing events, fusion transcripts, non-coding RNAs, and cellular pathway activity. RNA-sequencing technologies are increasingly utilized across oncology research, biomarker discovery, cell and gene therapy development, infectious disease monitoring, drug development, translational medicine, and clinical diagnostics. As healthcare and biopharmaceutical organizations seek deeper biological insights, transcriptomic sequencing is becoming a foundational technology for understanding disease mechanisms and supporting precision medicine initiatives. Advances in sequencing chemistry, bioinformatics, automation, and regulatory standardization are accelerating the transition of RNA-sequencing from research-focused applications toward regulated clinical and manufacturing environments.
Viral Safety Testing Is Expanding the Role of RNA-Sequencing in Bioprocessing
A significant industry trend is the growing adoption of RNA-sequencing for biosafety and quality assurance applications. Minaris strengthened this movement through the launch of AgentSCREEN, a GMP-qualified adventitious virus detection platform that utilizes transcriptomic NGS methodologies to evaluate mRNA samples for viral RNA transcripts. The platform is designed to support biopharmaceutical manufacturers seeking compliance with updated regulatory expectations such as ICH Q5A(R2), which increasingly recognize NGS as a highly sensitive alternative to traditional in vivo viral safety testing. This development reflects a broader industry shift toward sequencing-based approaches capable of improving viral detection sensitivity, accelerating biosafety assessments, and enhancing quality control processes within advanced biologics and cell therapy manufacturing environments.
Regulatory Standardization and Multiomic Integration Are Driving Industry Development
The industry is also benefiting from increasing regulatory attention focused on standardization, reproducibility, and data integrity. Health authorities are emphasizing harmonized protocols for library preparation, sequencing workflows, and bioinformatics analysis to ensure consistency across multi-center clinical studies and diagnostic applications. As RNA-sequencing becomes more widely adopted in regulated settings, companies are investing in Part 11-ready bioinformatics platforms that support GMP compliance, auditability, and clinical-grade data management. Simultaneously, advances in multiomic technologies are expanding the value of transcriptomic analysis. Illumina’s TruPath Genome solution, although primarily focused on whole-genome sequencing, provides enhanced resolution of previously inaccessible genomic regions and strengthens integrated genomic and transcriptomic workflows. Such developments enable more comprehensive characterization of disease biology by combining DNA and RNA insights within unified analytical frameworks. The convergence of transcriptomics, regulatory standardization, viral safety applications, and multiomic integration is positioning NGS-based RNA-sequencing as a strategic technology across research, diagnostics, and biopharmaceutical development.
NGS-based RNA-sequencing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global NGS-based RNA-sequencing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Illumina, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, BGI Genomics, Roche Sequencing Solutions, Qiagen N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., 10x Genomics, Eurofins Genomics. The NGS-based RNA-sequencing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the NGS-based RNA-sequencing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in NGS-based RNA-sequencing industry include- Illumina, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, BGI Genomics, Roche Sequencing Solutions, Qiagen N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., 10x Genomics, Eurofins Genomics. The NGS-based RNA-sequencing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US NGS-based RNA-sequencing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the NGS-based RNA-sequencing market remains one of the strongest-performing segments in the country.
The US NGS-based RNA-sequencing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US NGS-based RNA-sequencing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across NGS-based RNA-sequencing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian NGS-based RNA-sequencing markets
Canada's strong NGS-based RNA-sequencing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian NGS-based RNA-sequencing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany NGS-based RNA-sequencing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest NGS-based RNA-sequencing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of NGS-based RNA-sequencing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany NGS-based RNA-sequencing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the NGS-based RNA-sequencing market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support NGS-based RNA-sequencing sales through 2034
France NGS-based RNA-sequencing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK NGS-based RNA-sequencing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of NGS-based RNA-sequencing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China NGS-based RNA-sequencing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China NGS-based RNA-sequencing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of NGS-based RNA-sequencing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese NGS-based RNA-sequencing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India NGS-based RNA-sequencing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian NGS-based RNA-sequencing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil NGS-based RNA-sequencing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa NGS-based RNA-sequencing Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
NGS-based RNA-sequencing Market Segmentation
By Product and Service
Consumables
Sample Extraction and Purification Kits
Library Preparation Kits
Sequencing Reagents and Flow Cells
Instruments / Sequencing Platforms
Services
RNA-Sequencing Services
Bioinformatics and Data Analysis Services
By Technology
Sequencing by Synthesis (SBS)
Ion Torrent Semiconductor Sequencing
Nanopore Sequencing
Single-Molecule Real-Time (SMRT) Sequencing
By Sequencing Type
Whole Transcriptome Sequencing
Targeted RNA Sequencing
Single-Cell RNA Sequencing
By Application
Drug Discovery and Development
Clinical Diagnostics
Biomarker Discovery
Basic Agriculture and Life Science Research
By End-User
Pharmaceutical and Biotechnology Companies
Academic and Government Research Institutes
Clinical and Diagnostic Laboratories
Contract Research Organizations (CROs)
Leading Companies in NGS-based RNA-sequencing Industry (2026)
Illumina, Inc.
Thermo Fisher Scientific Inc.
Oxford Nanopore Technologies
BGI Genomics
Roche Sequencing Solutions
Qiagen N.V.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
10x Genomics
Eurofins Genomics
Countries Included
The NGS-based RNA-sequencing market report provides detailed analysis and outlook of NGS-based RNA-sequencing segments including By Product and Service (Consumables, Sample Extraction and Purification Kits, Library Preparation Kits, Sequencing Reagents and Flow Cells, Instruments / Sequencing Platforms, Services, RNA-Sequencing Services, Bioinformatics and Data Analysis Services), By Technology (Sequencing by Synthesis (SBS), Ion Torrent Semiconductor Sequencing, Nanopore Sequencing, Single-Molecule Real-Time (SMRT) Sequencing), By Sequencing Type (Whole Transcriptome Sequencing, Targeted RNA Sequencing, Single-Cell RNA Sequencing), By Application (Drug Discovery and Development, Clinical Diagnostics, Biomarker Discovery, Basic Agriculture and Life Science Research), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Clinical and Diagnostic Laboratories, Contract Research Organizations (CROs)) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
NGS-based RNA-Sequencing Industry Overview
Transcriptomics Is Becoming a Core Technology for Precision Medicine and Biopharmaceutical Development
The NGS-based RNA-sequencing industry has evolved into a critical segment of the broader genomics market, enabling comprehensive analysis of gene expression, transcript variants, alternative splicing events, fusion transcripts, non-coding RNAs, and cellular pathway activity. RNA-sequencing technologies are increasingly utilized across oncology research, biomarker discovery, cell and gene therapy development, infectious disease monitoring, drug development, translational medicine, and clinical diagnostics. As healthcare and biopharmaceutical organizations seek deeper biological insights, transcriptomic sequencing is becoming a foundational technology for understanding disease mechanisms and supporting precision medicine initiatives. Advances in sequencing chemistry, bioinformatics, automation, and regulatory standardization are accelerating the transition of RNA-sequencing from research-focused applications toward regulated clinical and manufacturing environments.
Viral Safety Testing Is Expanding the Role of RNA-Sequencing in Bioprocessing
A significant industry trend is the growing adoption of RNA-sequencing for biosafety and quality assurance applications. Minaris strengthened this movement through the launch of AgentSCREEN, a GMP-qualified adventitious virus detection platform that utilizes transcriptomic NGS methodologies to evaluate mRNA samples for viral RNA transcripts. The platform is designed to support biopharmaceutical manufacturers seeking compliance with updated regulatory expectations such as ICH Q5A(R2), which increasingly recognize NGS as a highly sensitive alternative to traditional in vivo viral safety testing. This development reflects a broader industry shift toward sequencing-based approaches capable of improving viral detection sensitivity, accelerating biosafety assessments, and enhancing quality control processes within advanced biologics and cell therapy manufacturing environments.
Regulatory Standardization and Multiomic Integration Are Driving Industry Development
The industry is also benefiting from increasing regulatory attention focused on standardization, reproducibility, and data integrity. Health authorities are emphasizing harmonized protocols for library preparation, sequencing workflows, and bioinformatics analysis to ensure consistency across multi-center clinical studies and diagnostic applications. As RNA-sequencing becomes more widely adopted in regulated settings, companies are investing in Part 11-ready bioinformatics platforms that support GMP compliance, auditability, and clinical-grade data management. Simultaneously, advances in multiomic technologies are expanding the value of transcriptomic analysis. Illumina’s TruPath Genome solution, although primarily focused on whole-genome sequencing, provides enhanced resolution of previously inaccessible genomic regions and strengthens integrated genomic and transcriptomic workflows. Such developments enable more comprehensive characterization of disease biology by combining DNA and RNA insights within unified analytical frameworks. The convergence of transcriptomics, regulatory standardization, viral safety applications, and multiomic integration is positioning NGS-based RNA-sequencing as a strategic technology across research, diagnostics, and biopharmaceutical development.
NGS-based RNA-sequencing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global NGS-based RNA-sequencing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Illumina, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, BGI Genomics, Roche Sequencing Solutions, Qiagen N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., 10x Genomics, Eurofins Genomics. The NGS-based RNA-sequencing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the NGS-based RNA-sequencing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth NGS-based RNA-sequencing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by NGS-based RNA-sequencing companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional NGS-based RNA-sequencing markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in NGS-based RNA-sequencing industry include- Illumina, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, BGI Genomics, Roche Sequencing Solutions, Qiagen N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., 10x Genomics, Eurofins Genomics. The NGS-based RNA-sequencing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US NGS-based RNA-sequencing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the NGS-based RNA-sequencing market remains one of the strongest-performing segments in the country.
The US NGS-based RNA-sequencing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US NGS-based RNA-sequencing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across NGS-based RNA-sequencing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian NGS-based RNA-sequencing markets
Canada's strong NGS-based RNA-sequencing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian NGS-based RNA-sequencing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany NGS-based RNA-sequencing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest NGS-based RNA-sequencing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of NGS-based RNA-sequencing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany NGS-based RNA-sequencing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the NGS-based RNA-sequencing market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support NGS-based RNA-sequencing sales through 2034
France NGS-based RNA-sequencing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK NGS-based RNA-sequencing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of NGS-based RNA-sequencing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China NGS-based RNA-sequencing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China NGS-based RNA-sequencing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of NGS-based RNA-sequencing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese NGS-based RNA-sequencing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India NGS-based RNA-sequencing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian NGS-based RNA-sequencing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil NGS-based RNA-sequencing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa NGS-based RNA-sequencing Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
NGS-based RNA-sequencing Market Segmentation
By Product and Service
Consumables
Sample Extraction and Purification Kits
Library Preparation Kits
Sequencing Reagents and Flow Cells
Instruments / Sequencing Platforms
Services
RNA-Sequencing Services
Bioinformatics and Data Analysis Services
By Technology
Sequencing by Synthesis (SBS)
Ion Torrent Semiconductor Sequencing
Nanopore Sequencing
Single-Molecule Real-Time (SMRT) Sequencing
By Sequencing Type
Whole Transcriptome Sequencing
Targeted RNA Sequencing
Single-Cell RNA Sequencing
By Application
Drug Discovery and Development
Clinical Diagnostics
Biomarker Discovery
Basic Agriculture and Life Science Research
By End-User
Pharmaceutical and Biotechnology Companies
Academic and Government Research Institutes
Clinical and Diagnostic Laboratories
Contract Research Organizations (CROs)
Leading Companies in NGS-based RNA-sequencing Industry (2026)
Illumina, Inc.
Thermo Fisher Scientific Inc.
Oxford Nanopore Technologies
BGI Genomics
Roche Sequencing Solutions
Qiagen N.V.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
10x Genomics
Eurofins Genomics
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential NGS-based RNA-sequencing Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the NGS-based RNA-sequencing Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NGS-BASED RNA-SEQUENCING MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global NGS-based RNA-sequencing Markets in 2026
3.2. Global Historic and Forecast NGS-based RNA-sequencing Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key NGS-based RNA-sequencing Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential NGS-based RNA-sequencing Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across NGS-based RNA-sequencing Value Chain
CHAPTER 4- NGS-BASED RNA-SEQUENCING MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading NGS-based RNA-sequencing Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NGS-BASED RNA-SEQUENCING MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product and Service
Consumables
Sample Extraction and Purification Kits
Library Preparation Kits
Sequencing Reagents and Flow Cells
Instruments / Sequencing Platforms
Services
RNA-Sequencing Services
Bioinformatics and Data Analysis Services
By Technology
Sequencing by Synthesis (SBS)
Ion Torrent Semiconductor Sequencing
Nanopore Sequencing
Single-Molecule Real-Time (SMRT) Sequencing
By Sequencing Type
Whole Transcriptome Sequencing
Targeted RNA Sequencing
Single-Cell RNA Sequencing
By Application
Drug Discovery and Development
Clinical Diagnostics
Biomarker Discovery
Basic Agriculture and Life Science Research
By End-User
Pharmaceutical and Biotechnology Companies
Academic and Government Research Institutes
Clinical and Diagnostic Laboratories
Contract Research Organizations (CROs)
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America NGS-based RNA-sequencing Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
7.5. North America NGS-based RNA-sequencing Market Size Outlook by Type
7.6. North America NGS-based RNA-sequencing Market Size Outlook by Application
7.7. North America NGS-based RNA-sequencing Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US NGS-based RNA-sequencing Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada NGS-based RNA-sequencing Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico NGS-based RNA-sequencing Companies
CHAPTER 8- EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe NGS-based RNA-sequencing Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
8.5. Europe NGS-based RNA-sequencing Market Size Outlook by Type
8.6. Europe NGS-based RNA-sequencing Market Size Outlook by Application
8.7. Europe NGS-based RNA-sequencing Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany NGS-based RNA-sequencing Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France NGS-based RNA-sequencing Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK NGS-based RNA-sequencing Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain NGS-based RNA-sequencing Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy NGS-based RNA-sequencing Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe NGS-based RNA-sequencing Companies
CHAPTER 9- ASIA PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific NGS-based RNA-sequencing Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific NGS-based RNA-sequencing Market Size Outlook by Type
9.6. Asia Pacific NGS-based RNA-sequencing Market Size Outlook by Application
9.7. Asia Pacific NGS-based RNA-sequencing Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China NGS-based RNA-sequencing Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan NGS-based RNA-sequencing Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India NGS-based RNA-sequencing Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea NGS-based RNA-sequencing Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia NGS-based RNA-sequencing Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia NGS-based RNA-sequencing Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America NGS-based RNA-sequencing Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
10.5. South and Central America NGS-based RNA-sequencing Market Size Outlook by Type
10.6. South and Central America NGS-based RNA-sequencing Market Size Outlook by Application
10.7. South and Central America NGS-based RNA-sequencing Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil NGS-based RNA-sequencing Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina NGS-based RNA-sequencing Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America NGS-based RNA-sequencing Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa NGS-based RNA-sequencing Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa NGS-based RNA-sequencing Market Size Outlook by Type
11.6. Middle East and Africa NGS-based RNA-sequencing Market Size Outlook by Application
11.7. Middle East and Africa NGS-based RNA-sequencing Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia NGS-based RNA-sequencing Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE NGS-based RNA-sequencing Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa NGS-based RNA-sequencing Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in NGS-based RNA-sequencing Industry
Illumina, Inc.
Thermo Fisher Scientific Inc.
Oxford Nanopore Technologies
BGI Genomics
Roche Sequencing Solutions
Qiagen N.V.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
10X GENOMICS
Eurofins Genomics
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential NGS-based RNA-sequencing Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the NGS-based RNA-sequencing Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NGS-BASED RNA-SEQUENCING MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global NGS-based RNA-sequencing Markets in 2026
3.2. Global Historic and Forecast NGS-based RNA-sequencing Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key NGS-based RNA-sequencing Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential NGS-based RNA-sequencing Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across NGS-based RNA-sequencing Value Chain
CHAPTER 4- NGS-BASED RNA-SEQUENCING MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading NGS-based RNA-sequencing Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NGS-BASED RNA-SEQUENCING MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product and Service
Consumables
Sample Extraction and Purification Kits
Library Preparation Kits
Sequencing Reagents and Flow Cells
Instruments / Sequencing Platforms
Services
RNA-Sequencing Services
Bioinformatics and Data Analysis Services
By Technology
Sequencing by Synthesis (SBS)
Ion Torrent Semiconductor Sequencing
Nanopore Sequencing
Single-Molecule Real-Time (SMRT) Sequencing
By Sequencing Type
Whole Transcriptome Sequencing
Targeted RNA Sequencing
Single-Cell RNA Sequencing
By Application
Drug Discovery and Development
Clinical Diagnostics
Biomarker Discovery
Basic Agriculture and Life Science Research
By End-User
Pharmaceutical and Biotechnology Companies
Academic and Government Research Institutes
Clinical and Diagnostic Laboratories
Contract Research Organizations (CROs)
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America NGS-based RNA-sequencing Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
7.5. North America NGS-based RNA-sequencing Market Size Outlook by Type
7.6. North America NGS-based RNA-sequencing Market Size Outlook by Application
7.7. North America NGS-based RNA-sequencing Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US NGS-based RNA-sequencing Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada NGS-based RNA-sequencing Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico NGS-based RNA-sequencing Companies
CHAPTER 8- EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe NGS-based RNA-sequencing Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
8.5. Europe NGS-based RNA-sequencing Market Size Outlook by Type
8.6. Europe NGS-based RNA-sequencing Market Size Outlook by Application
8.7. Europe NGS-based RNA-sequencing Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany NGS-based RNA-sequencing Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France NGS-based RNA-sequencing Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK NGS-based RNA-sequencing Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain NGS-based RNA-sequencing Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy NGS-based RNA-sequencing Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe NGS-based RNA-sequencing Companies
CHAPTER 9- ASIA PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific NGS-based RNA-sequencing Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific NGS-based RNA-sequencing Market Size Outlook by Type
9.6. Asia Pacific NGS-based RNA-sequencing Market Size Outlook by Application
9.7. Asia Pacific NGS-based RNA-sequencing Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China NGS-based RNA-sequencing Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan NGS-based RNA-sequencing Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India NGS-based RNA-sequencing Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea NGS-based RNA-sequencing Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia NGS-based RNA-sequencing Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia NGS-based RNA-sequencing Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America NGS-based RNA-sequencing Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
10.5. South and Central America NGS-based RNA-sequencing Market Size Outlook by Type
10.6. South and Central America NGS-based RNA-sequencing Market Size Outlook by Application
10.7. South and Central America NGS-based RNA-sequencing Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil NGS-based RNA-sequencing Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina NGS-based RNA-sequencing Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America NGS-based RNA-sequencing Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa NGS-based RNA-sequencing Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa NGS-based RNA-sequencing Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa NGS-based RNA-sequencing Market Size Outlook by Type
11.6. Middle East and Africa NGS-based RNA-sequencing Market Size Outlook by Application
11.7. Middle East and Africa NGS-based RNA-sequencing Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia NGS-based RNA-sequencing Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE NGS-based RNA-sequencing Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa NGS-based RNA-sequencing Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa NGS-based RNA-sequencing Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in NGS-based RNA-sequencing Industry
Illumina, Inc.
Thermo Fisher Scientific Inc.
Oxford Nanopore Technologies
BGI Genomics
Roche Sequencing Solutions
Qiagen N.V.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
10X GENOMICS
Eurofins Genomics
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
